Exhibit 99.80
 
  MILESTONES MET IN 2009 LEAD TO OPTIMISTIC OUTLOOK FOR THERATECHNOLOGIES
 Theratechnologies announces financial results for the fourth quarter
and reviews highlights for the year 2009
 
    
    Conclusion of an agreement with EMD Serono
    
    Filing of a New Drug Application with the FDA
    
    Receipt of a US $10 M milestone payment
    
    Invitation to appear before a FDA Advisory Committee
    
    Granting of a patent for tesamorelin in Brazil
    
    $65 M liquidity position
 Montréal, Canada  February 10, 2010
   Highlights
 Agreement signed with EMD Serono
  Submission of a New Drug Application to the FDA
  Theratechnologies Inc.    




---



##### 



Receipt of a US $10 M milestone payment
  Invitation to appear before a FDA Advisory Committee
  Issuance of a patent for tesamorelin in Brazil
 Chimeric fatty body-pro-GRF analog with increased biological potency and pharmaceutical
formulation




---



##### 



MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE FOURTH QUARTER
 Revenues
  Royalties, technologies and other
    Interest
  R&D Activities




---



##### 



Other Expenses
     Net Results
   Quarterly Financial Information
 Goodwill and Intangible Assets
  2009
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2008Q4
    
    
    Q3
    
    
    Q2
    
    
    Q1
    
    
    Q4
    
    
    Q3
    
    
    Q2
    
    
    Q1Revenues
    
    $
    2,246
    
    
    $
    13,148
    
    
    $
    2,317
    
    
    $
    2,009
    
    
    $
    616
    
    
    $
    710
    
    
    $
    716
    
    
    $
    599Net earnings (net loss)
    
    $
    (4,698
    )
    
    $
    5,824
    
    
    $
    (5,430
    )
    
    $
    (10,754
    )
    
    $
    (15,145
    )
    
    $
    (11,220
    )
    
    $
    (11,382
    )
    
    $
    (10,864
    )Basic and
diluted benefit (loss) per share
    
    $
    (0.08
    )
    
    $
    0.10
    
    
    $
    (0.09
    )
    
    $
    (0.18
    )
    
    $
    (0.26
    )
    
    $
    (0.19
    )
    
    $
    (0.20
    )
    
    $
    (0.20
    )




---



##### 



Financial Position
    Subsequent Events
 Shareholder rights plan




---



##### 



Granting of stock options
  New Accounting Policies
  Goodwill and Intangible Assets
 Outstanding Share Data
  Contractual Obligations
   Economic and Industry Factors
  About Theratechnologies
  Additional Information about Theratechnologies
 www.theratech.com  www.sedar.com
 Forward-Looking Information




---



##### 



www.sedar.com
 Information:
 communications@theratech.com
 ltanguay@theratech.com




---



##### 



ANNEX A
 Non-GAAP measures
  Definition and reconciliation of non-GAAP measures
   November 30th
    
    
    November 30th(3 months)
    
    
    (12 months)Adjusted net loss
    
    2009
    
    
    2008
    
    
    2009
    
    
    2008Net loss, per the financial statements
    
    $
    (4,698
    )
    
    $
    (15,145
    )
    
    $
    (15,058
    )
    
    $
    (48,611
    )Adjustments:Revenues associated with a collaboration and license
agreement (note 7 to the consolidated financial
statements)
    
    
    (1,711
    )
    
    
    
    
    
    
    (17,444
    )
    
    
    Fees associated with collaboration and license
agreement
    
    
    
    
    
    
    
    
    
    
    4,269
    
    
    
    Adjusted net loss
    
    $
    (6,409
    )
    
    $
    (15,145
    )
    
    $
    (28,233
    )
    
    $
    (48,611
    )
 November 30th
    
    
    November 30thAdjusted burn rate before changes in operating
    
    (3 months)
    
    
    (12 months)assets and liabilities
    
    2009
    
    
    2008
    
    
    2009
    
    
    2008Burn rate before changes in operating assets and
liabilities, per the financial statements
    
    $
    (4,333
    )
    
    $
    (9,559
    )
    
    $
    (13,547
    )
    
    $
    (41,592
    )Adjustments:Revenues associated with a collaboration and license
agreement (note 7 to the consolidated financial
statements)
    
    
    (1,711
    )
    
    
    
    
    
    
    (17,444
    )
    
    
    Fees associated with collaboration and license
agreement
    
    
    
    
    
    
    
    
    
    
    4,269
    
    
    
    Adjusted burn rate before changes in operating
assets and liabilities
    
    $
    (6,044
    )
    
    $
    (9,559
    )
    
    $
    (26,722
    )
    
    $
    (41,592
    )